血清ALD和sE-Cad检测在TAE治疗原发性肝癌中的意义

The significance of the measurement of fructose 1,6-disphosphate aldolase and soluble E-cadherin in transcatheter arterial embolization for hepatocellualcarcinoma

为探讨血清1,6-二磷酸果糖醛缩酶(ALD)和可溶性上皮型钙粘蛋白(sE-Cad)检测对行经皮肝动脉灌注化疗栓塞术(TAE)治疗原发性肝癌疗效的临床价值,对46例原发性肝癌行TAE术后监测各阶段患者血清ALD、sE-Cad及甲胎蛋白(AFP)的变化并进行比较,结果显示,ALD活性变化反映了肝癌组织的坏死程度,sE-Cad及AFP水平随治疗进行呈下降趋势,ALD活性及sE-Cad水平术前、术后比较均有显著性差异P<0.05,血清ALD活性及sE-Cad水平检测均可用于TAE治疗原发性肝癌的疗效评价,特别是对AFP阴性的肝癌患者的疗效判断有较大的临床应用价值。

To evaluate the value of fructose 1, 6 - Diphosphate Aldolase （ALD） and Soluble E - Cadherin （ sE - Cad） on treating hepatocellular carcinoma （HCC） by transcatheter atterical Embolization （TAE）. There are 46 patients treated with TAE. The changes of serum levels of ALD and sE - Cad were analyzed in different stages after TAE. And the levels of the serum alpha- fetoprotein（AFP） were also analyzed. The results showed that the changes in serum levels of ALD indicated necrosis degree of tumor tissue in HCC. And the levels of sE - Cad and AFP in serum were reduced with developing of treatment. The levels of ALD and sE - Cad in serum there were obvious differentia after TAE treatment than before that （ P 〈 0. 05 ）. Levels of ALD and sE - Cad in serum after TAE treatment were clinically useful to evaluate HCC, especially for the patients with low AFP.